Summary:
Albiglutide is designed with intentions of improving your T2D and your quality of life by removing the need for daily injections, potentially offering a more convenient dosing regimen in T2D.
Academy of Clinical Research is evaluating the efficacy and safety of a weekly subcutaneously injected dose of Albiglutide as compared with Sitagliptin.
Subjects who are renally impaired with a historical diagnosis of type 2 diabetes mellitus and whose glucose level is inadequately controlled on their current regimen of diet and exercise or their antidiabetic therapy of metformin, thiazolidinedione, sulfonylurea, or any combination of these oral antidiabetic medications will be recruited into the study.
Qualified Participants Must:
• Be 18 years of age or older
•
Be renally impaired with a historical diagnosis of type 2 diabetes mellitus and experiencing inadequate sugar control on their current regime of diet and exercise or their antidiabetic therapy
•
Have a BMI >20 kg/m2 and < 45 kg/m2
•
Have fasting C-peptide > 0.8 ng/mL
•
Have HbA1c between 7.0% and 10.0%
•
Have Hemoglobin >10 g/dL for males and > g/dL for females
•
Be able and willing to monitor own blood glucose concentrations with a home glucose monitor
•
Have no major illness or debility that in our doctors’ opinion prohibits the subject from actively participating in their diabetes management and completing the study
Qualified Participants May Receive:
Will be discussed during screening and informed consent process.